| Market Capitalization (Millions $) |
465 |
| Shares
Outstanding (Millions) |
72 |
| Employees |
2,602 |
| Revenues (TTM) (Millions $) |
386 |
| Net Income (TTM) (Millions $) |
-199 |
| Cash Flow (TTM) (Millions $) |
0 |
| Capital Exp. (TTM) (Millions $) |
0 |
Business Description
Sinovac Biotech Ltd is a biopharmaceutical company headquartered in Beijing, China. It was established in 1999 and specializes in research, development, manufacturing and commercialization of vaccines for various infectious diseases.
Sinovac has a strong pipeline of vaccines, which cover a broad range of diseases such as hepatitis A, hepatitis B, influenza, human rabies, human papillomavirus (HPV), Japanese encephalitis, enterovirus 71, and SARS-CoV-2. The companyes experience in vaccine development has allowed it to be recognized globally as a pioneer in the field of vaccine R&D.
One of Sinovaces most significant achievements is the development of the inactivated vaccine against COVID-19, CoronaVac. CoronaVac has been approved for emergency distribution in many countries, including Brazil, Chile, Indonesia, and Turkey. The vaccine has undergone three phases of clinical trials, showing an efficacy rate of 91.25% after two doses in phase III trials in Turkey, and has been distributed globally through a network of partners and agents.
Apart from COVID-19, Sinovaces other key products include Healive, an inactivated hepatitis A vaccine; Anflu, a split-virion influenza vaccine; Panflu, a pandemic H1N1 influenza vaccine; and Ev71 vaccine, a vaccine against hand, foot, and mouth disease.
Sinovac has four production facilities; three in China, and one in Brazil. The companyes state-of-the-art manufacturing facilities have the capacity to produce more than 300 million doses of vaccines annually. The company has partnerships with many pharmaceutical companies in China, Europe, Latin America, and other regions, which help distribute its products globally.
Apart from vaccine development, Sinovac is committed to providing affordable and accessible vaccines to people. The company has collaborated with many local organizations to set up vaccination programs, especially in underdeveloped countries.
In conclusion, Sinovac Biotech is a highly respected and prominent biopharmaceutical company that is focused on providing innovative vaccines to the worldes population. The company is at the forefront of vaccine development and has played a significant role in fighting pandemics such as COVID-19, hepatitis A, and influenza. Its dedication to producing safe and effective vaccines at an affordable price has made it a leading player in the global vaccine industry.
Company Address: No. 39 Shangdi Xi Road Beijing 100085
Company Phone Number: 10-5693-1800 Stock Exchange / Ticker: NASDAQ SVA
|
0.000%
6.48 %